SLAMF7 modulators(SLAM family member 7 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Natural killer cells stimulants(Natural killer cells stimulants)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Multiple MyelomaImmunoglobulin deposition diseaseImmunoglobulin Light-Chain Amyloidosis

Inactive Indication

Immunoglobulin G4-Related DiseaseKidney Failure, ChronicMyelofibrosis+ [3]

Originator Organization

PDL BioPharma, Inc.

Active Organization

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIG

AbbVie, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (30 Nov 2015),

Multiple Myeloma

RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (JP)

Structure/Sequence

Sequence Code 9930317H

Source: *****

Sequence Code 9930324L

Source: *****

Clinical Trials associated with Elotuzumab

NCT06785415

/ Not yet recruitingPhase 1/2IIT

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Elotuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving iberdomide in combination with daratumumab, elotuzumab, and dexamethasone may be safe, tolerable and/or effective in patients with relapsed multiple myeloma.

Start Date03 Mar 2025

Sponsor / Collaborator

Mayo Clinic

NCT06518551

/ RecruitingPhase 1/2IIT

A Phase I/II Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
The names of the study drugs involved in this study are:
* Iberdomide (a type of cereblon E3 ligase modulator)
* Elotuzumab (a type of monoclonal antibody)
* Dexamethasone (a type of steroid)

Start Date01 Nov 2024

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+2]

NCT06158841

/ RecruitingPhase 3

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM.
Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world.
In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Start Date19 May 2024

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Elotuzumab

100 Translational Medicine associated with Elotuzumab

100 Patents (Medical) associated with Elotuzumab

378

Literatures (Medical) associated with Elotuzumab

01 Feb 2025·ESMO Open

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients

Article

Author: Conticello, C ; Musso, M ; Amico, V ; Martino, E A ; Accardi, F ; Casaluci, G M ; Palmieri, S ; Bruzzese, A ; Franceschini, L ; Uccello, G ; Barbieri, E ; Offidani, M ; Cerchione, C ; Zambello, R ; Gozzetti, A ; Maroccia, A ; Palumbo, G ; De Magistris, C ; Tarantini, G ; Derudas, D ; Brunori, M ; Petrucci, M T ; Quaresima, M ; Barilà, G ; Pettine, L ; Vigna, E ; Galli, M ; Morabito, F ; Neri, A ; Mele, G ; Califano, C ; Sgherza, N ; Vincelli, I D ; Di Renzo, N ; Mina, R ; Zamagni, E ; Fontana, R ; Rizzi, R ; Mancuso, K ; Reddiconto, G ; Bertuglia, G ; Curci, P ; Ria, R ; Amendola, A ; Di Raimondo, F ; Nappi, D ; Musto, P ; Bongarzoni, V ; Rago, A ; Rossini, B ; Mangiacavalli, S ; Della Pepa, R ; Gentile, M ; Tripepi, G ; Cotzia, E

BACKGROUND:

Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).

MATERIALS AND METHODS:

This retrospective analysis included 247 Dara-R MM patients treated with EloPd. All patients were also refractory to lenalidomide, with 51.4% to a proteasome inhibitor, thus classified as triple-class refractory (TCR). Survival risk-scoring systems for PFS (progression-free risk score-PRS_DaraR) and OS (survival risk score-SRS_DaraR) were developed to stratify patients based on their risk profiles.

RESULTS:

The overall response rate was 52.6%, with a median PFS and OS of 6.6 and 17.0 months, respectively. The International Staging System (ISS) stages II and III, low hemoglobin (Hb) levels, the last therapy being daratumumab, and symptomatic relapse were identified as significant independent predictors of shorter PFS in multivariable analysis. In addition to advanced ISS stages, low Hb levels (<10.6 g/dl), symptomatic relapse, and refractory disease exhibited an independent negative impact on OS. Importantly, no significant differences in both PFS and OS were observed between TCR and non-TCR patients. Based on these multivariable analyses, we developed PRS_DaraR and SRS_DaraR according to the magnitude of the hazard ratio. In PRS_DaraR, 10.1% were low-risk, 41.3% intermediate, 43.3% high, and 5.3% very high-risk. The 12-month PFS probabilities were 86.3% (low), 67.6% (intermediate), 52.9% (high), and 31.8% (very high). For SRS_DaraR, 6.1% were low-risk, 47.8% intermediate, 19.4% high, and 26.7% very high. The 12-month OS probabilities were 90.9% (low), 75.7% (intermediate), 55.9% (high), and 32.6% (very high).

CONCLUSIONS:

This study supports EloPd as an effective treatment option in Dara-R MM patients, providing valuable disease control and acting as a potential bridge to newer therapies, such as CAR-T and bispecific antibodies.

01 Feb 2025·EJHaem

Angioimmunoblastic T‐cell lymphoma: Characterization of clonal T and B cells and a patient‐derived xenograft study of coexisting T‐ and B‐cell proliferation

Article

Author: Bodo, Juraj ; Jagadeesh, Deepa ; Hsi, Eric D ; Zhao, Xiaoxian ; Ondrejka, Sarah L ; Durkin, Lisa ; Lindner, Daniel J

Abstract:

Introduction:

Angioimmunoblastic T‐cell lymphoma (AITL) is a rare and aggressive lymphoma with a poor prognosis. AITL is associated with Epstein–Barr virus (EBV)‐positive B cells in most cases, suggesting a possible role for the virus in the pathobiology of AITL. Cell lines from AITL patients do not exist and models of human AITL are needed. We aim to establish such a model and use it for preclinical therapeutic evaluation.

Methods:

Primary lymph node tissue from an AITL patient was used for tumor cell isolation and injection to NSG mice. The established patient‐derived xenograft (PDX) model was characterized by immunophenotyping, whole‐exome sequencing (WES), and T/B‐cell receptor gene rearrangement studies. In vivo AITL PDX trials were performed with elotuzumab, romidepsin, and rituximab.

Results:

An AITL PDX mouse model that includes a coexisting EBV+ B‐cell proliferation was established. We confirmed clonal identity of the engrafted T cells with the primary T‐lymphoma cells. WES on DNA from xenografted sorted T and B cells identified eight and three mutations previously reported in the COSMIC database, respectively. Primary tumor cells could be passaged serially in NSG mice with an increasing percentage of monoclonal B cells that mimic the human condition in which the clonal B‐cell component in some cases may mask an underling T‐cell lymphoma. In this PDX mouse study, single agent elotuzumab or rituximab significantly improved mice survival. Survival was further improved when elotuzumab or romidepsin was combined with rituximab.

Conclusion:

To our knowledge, this is the first molecular characterization of AITL model coexisting with associated EBV+ B cells, and use of such a PDX model for therapeutic evaluation of agents targeting both malignant T cells and B cells simultaneously.

01 Feb 2025·CANCER SCIENCE

Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction

Article

Author: Maruhashi, Tomoko ; Teramachi, Jumpei ; Fujii, Shiro ; Hiasa, Masahiro ; Kagawa, Kumiko ; Takahashi, Mamiko ; Ozaki, Shuji ; Endo, Itsuro ; Nakamura, Shingen ; Hara, Tomoyo ; Oura, Masahiro ; Sumitani, Ryohei ; Maeda, Yusaku ; Tenshin, Hirofumi ; Sogabe, Kimiko ; Miki, Hirokazu ; Harada, Takeshi ; Inoue, Yusuke ; Abe, Masahiro ; Oda, Asuka

Abstract:

Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1‐like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL‐2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody‐dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti‐SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7‐expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance γδ T cell‐induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor‐κ B ligand and M‐CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo‐expanded γδ T cells can exert ELO‐mediated ADCC against SLAMF7‐expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of γδ T cells.

News (Medical) associated with Elotuzumab

24 Jan 2025

·www.drugs.com

Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma

FRIDAY, Jan. 24, 2025 -- For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood . Rahul Banerjee, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues conducted a secondary pooled analysis of the SWOG 0777 and SWOG 1211 studies, which examined lenalidomide and dexamethasone alone, with or without bortezomib and with or without elotuzumab for NDMM. In all arms, the planned dexamethasone intensity was 40 to 60 mg weekly. Patients were classified as full-dose dexamethasone throughout induction (FD-DEX) or lowered-dose dexamethasone or discontinuation (LD-DEX), permitted for grade 3+ toxicities per both study protocols. The LD-DEX group included 373 patients (69 percent) of the 541 evaluated. The researchers found that progression-free survival (PFS) and overall survival (OS) did not differ between the FD-DEX and LD-DEX groups. In the multivariate models, predictors of PFS and OS were treatment arm, age 70 years or older, and thrombocytopenia. "Dexamethasone dose reductions <40 to 60 mg per week are quite common even in the setting of clinical trials," the authors write. "These dose reductions do not appear to negatively impact PFS or OS. We encourage future trials to investigate lowered-dose dexamethasone strategies prospectively, either at treatment onset or within a few cycles of treatment initiation." Several authors disclosed ties to the biopharmaceutical industry.

Clinical Result

05 Jun 2024

·www.prnewswire.com

AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared with standard available therapies (SATs) in patients with r/r MM who have received at least two lines of prior therapy NORTH CHICAGO, Ill., June 5, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.1 ABBV-383 is being evaluated in a Phase 3, multicenter, randomized, open-label study compared with standard available therapies in patients with r/r MM who received at least two lines of prior therapy. "Despite notable advances in treatment, most patients with multiple myeloma will eventually relapse. Patients with advanced disease, especially in the community setting, often have limited access to novel treatment options and existing options have a high treatment burden, including frequent dosing," said Dr. Peter Voorhees, clinical professor of medicine, director of plasma cell disorders, Atrium Health Levine Cancer Institute. "The CERVINO Phase 3 trial is designed to evaluate the efficacy of ABBV-383 with monthly dosing and we look forward to seeing the data as it emerges." Multiple myeloma is a blood cancer characterized by abnormal proliferation of plasma cells, which can cause end-organ damage and is the second most commonly occurring blood cancer in the world.2 An estimated 176,000 people globally were diagnosed with multiple myeloma in 2020, and 117,000 people died from the disease.3 "The start of the CERVINO Phase 3 trial marks an important step forward in AbbVie's continued commitment to advance new oncology treatments and elevate the standard of care for blood cancer patients," said Mariana Cota Stirner, M.D., vice president, therapeutic area head oncology, hematology, AbbVie. "ABBV-383 is being evaluated with monthly dosing from the beginning of treatment, with the goal of maximizing treatment simplicity for physicians and patients, if proven in the clinical trials." About the CERVINO Study CERVINO (NCT06158841) is a global, Phase 3, multicenter, randomized, open-label, parallel-group study evaluating ABBV-383 in adult patients (≥18 years) with r/r MM and an Eastern Cooperative Oncology Group performance status ≤2 who received at least two prior lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb. Patients who received prior BCMA-targeted therapy will be excluded. Patients will be randomized 1:1 to receive intravenous ABBV-383 60mg Q4W or the investigator's choice of SAT (carfilzomib + dexamethasone, elotuzumab + pomalidomide + dexamethasone, or selinexor + bortezomib + dexamethasone), and will continue treatment until confirmed progressive disease or other discontinuation criteria are met. The dual primary end points are progression-free survival and overall response rate. Secondary end points include overall survival, complete response (CR) or better, very good partial response or better, rate of minimum residual disease negativity, and change in disease symptoms and physical functioning. Approximately 140 sites globally will enroll approximately 380 total patients. Additional information about the study can be found at under the identifier NCT06158841. About ABBV-383 ABBV-383 is an investigational distinctive BCMA x CD3 bispecific antibody T-cell engager composed of bivalent high-avidity BCMA-binding domains, a low-affinity CD3-binding domain designed to reduce cytokine release, and a silenced Fc tail designed for an extended half-life that may support once every 4-week (Q4W) dosing. Clinical relevance of these structure activity relationships has not been established. BCMA is highly expressed on the surface of malignant plasma cells in multiple myeloma, making it an ideal target for therapy. BCMA plays a crucial role in the survival of myeloma cells by promoting their growth and inhibiting their apoptosis (programmed cell death).4 About AbbVie in Oncology At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, and bi-specific and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio is comprised of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit us at . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 1 Foureau DM, Bhutani M, Robinson M, et al: Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma. EJHaem 1:113-121, 2020 2 International Myeloma Foundation. What is Multiple Myeloma? 3 Cancer.Net. Multiple Myeloma: Statistics. . 4 Cho SF, Anderson KC, Tai YT: Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 9:1821, 2018 SOURCE AbbVie

Phase 3ImmunotherapyASCO

22 May 2024

·www.biospace.com

Multiple Myeloma Antibody Combinations Clinical Trials Insight

“Currently 65 Antibodies Combinations Are Approved For Various Cancer Treatments” The treatment landscape for multiple myeloma ailment is a rapidly evolving field with ongoing research and clinical trials aimed at better understanding these conditions and developing effective therapies. Multiple myeloma is a group of hematological malignancies disorders characterized by the abnormalities in plasma cells, a type of white blood cell. With the rising incidence as well as prevalence of multiple myeloma year by year led to the development of novel combination therapies which can target these ailments. In the recent year, finding for the need of novel treatments led to the discovery of antibody combinations used for the treatment of multiple myeloma. The research and development of antibody combinations for the treatment of multiple myeloma begin when the monoclonal antibodies (mAbs), daratumumab (Darzalex) in addition elotuzumab (Empliciti), have aided to expand the treatment options for multiple myeloma and thereby led to great improvement in patient outcome. The mechanism used by these antibodies is to target the signaling lymphocytic activation molecule family 7 (SLAMF7)/ CD319 or CD38 that are frequently overexpressed in multiple myeloma cells. On the account of that reason, several antibody combinations, like Sarclisa (isatuximab-irfc), in combination with pomalidomide (Pomalyst) and dexamethasone, Sarclisa in combination with carfilzomib (Kyprolis) and dexamethasone, and Darzalex Faspro, Kyprolis, and Dexamethasone were approved in the 2020 and 2021 for the treatment of adult patients with relapsed or refractory multiple myeloma. Download Research Insight: Since the discovery of antibody combinations involved for the treatment of multiple myeloma, there has been significant research into understanding the mode of action of antibody has been completed. Studies have focused on developing treatments that can prevent the abnormal aggregation of plasma cells or mitigate its toxic effects. Succeeding the approval of antibody combination, many clinical as well as translational research are being initiated in the arena with the intention to develop and innovative and advanced antibody combination treatment regimen which will aid to provide treatment for numerous patients suffering from multiple myeloma malignancies. Currently, numerous clinical researches are ongoing in the realm, few of which have reached the late stage of development that are being conducted by various pharma companies and hospitals such as Sanofi, Pfizer, Wuerzburg University Hospital, ClinAssess GmbH, Arbeitsgemeinschaft medikamentoese Tumortherapie, SWOG Cancer Research Network, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group, Eastern Cooperative Oncology Group, European Myeloma Network, Karyopharm Therapeutics, GlaxoSmithKline, Janssen Research & Development, Alexion Pharmaceuticals etc. Apart from the involvement of various stakeholders from the giant pharma companies, the pipeline for sphere of antibody combinations for the treatment of multiple myeloma consist of monoclonal and bispecific antibodies targeting immune checkpoint receptors like anti PD-1, anti PD-L1, anti CTLA-4 along with BCMA, CD3, OX40, CD38, GPRC5D directed CD3 bispecific antibodies, interleukin- 6 receptor mAbs along with gamma secretase inhibitor. Presence of different types of therapeutic agents with antibody illustrates that the realm of antibody combinations to treat multiple myeloma is growing and it is expected that multiple novel combinations will be launch in the upcoming years. The vista of antibody combination therapy for the treatment of multiple myeloma is expanding at an incredible gait on the account of the rising growth of antibody combinations in the commercial market along with augmenting partnerships, increasing research, investments and collaborations in the domain. For instance, in January 2024, a researcher at Penn State Cancer Institute based in the US, stated that the bispecific antibodies plays a significant role for the treatment of in hematologic malignancies, particularly multiple myeloma. Despite the fact that chimeric antigen receptor (CAR)-T cell therapy have made surplus benefits to patients, yet the role of bispecific antibodies becomes progressively apparent in the difficult-to-treat population with multiple myeloma patients. Antibody combinations represent a significant breakthrough in the management of multiple myeloma. By targeting the key pathway and receptors such as SLAMF7/ CD319 or CD38 that are involved in progression of multiple myeloma, the therapeutic approach offer an effective and convenient way to increase effectiveness and reduce the side effects along with drug resistances. Despite some challenges, Antibody combinations clenches great promise in transforming the lives of those suffering from multiple myeloma, providing a beacon of aspiration to numerous individuals suffering from multiple myeloma. As research continues, the use of antibody combination therapies may become more refined and accessible treatment, further improving their role in multiple myeloma management.

ImmunotherapyDrug Approval

100 Deals associated with Elotuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09337	Elotuzumab	L01XC23	DB06317

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	US	Bristol Myers Squibb Co.	30 Nov 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	US	AbbVie, Inc.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	US	Bristol Myers Squibb Co.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	JP	AbbVie, Inc.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	JP	Bristol Myers Squibb Co.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	AU	Bristol Myers Squibb Co.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	AU	AbbVie, Inc.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	AT	AbbVie, Inc.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	AT	Bristol Myers Squibb Co.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	BE	Bristol Myers Squibb Co.	20 Jun 2011
Refractory Multiple Myeloma	Phase 3	BE	AbbVie, Inc.	20 Jun 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04918147 (CTgov)	Phase 2	Immunoglobulin G4-Related Disease	8	Elotuzumab+Prednisone (Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone Taper)	djecxcuxpu(abfrvgzbso) = rlrwfmewnh cusyukwjnm (ccfdixlcxx, obriqjanjl - yylbcqhfpv) View more	-	25 Feb 2025
				Elotuzumab+Prednisone (Cohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper)	djecxcuxpu(abfrvgzbso) = mwcjahdyds cusyukwjnm (ccfdixlcxx, tnxsojmepi - eqgcdmfxvt) View more
NCT02420860 (phase II study of lenalidomide-elotuzumab, ASCO2024)	Phase 2	Multiple Myeloma Maintenance	100	Lenalidomide-elotuzumab	acyzdnsgeb(hpzkaixxbg) = aotelvelxc xqfwxodcqt (bnjdmsvywr ) View more	Positive	24 May 2024
ELOQUENT 2 and 3 (EHA2024)	Not Applicable	Multiple Myeloma	135	Elo-Len-Dex (ERd)	hzeahqzhti(tgpvtpakod) = ztvolkgmkr uunrljsoyq (zhkwhffxhb ) View more	Positive	14 May 2024
				Elo-Pom-Dex (EPd)	hzeahqzhti(tgpvtpakod) = oxuscpynnz uunrljsoyq (zhkwhffxhb, 4.08 for high - risk vs. 6.12 for standard risk pts) View more
NCT02495922 (GMMG-HD6, Pubmed) Manual	Phase 3	Multiple Myeloma Consolidation \| First line \| Induction	559	RVdVelcadeRevlimidDexamethasonelenalidomide	oumforkhst(ipzrruixgo) = ucozfbbxam nmednbchzu (wknybvgjsg, 61 - 76) View more	Negative	01 Feb 2024
				RVd/E-RVelcadeRevlimidDexamethasonelenalidomideelotuzumab	oumforkhst(ipzrruixgo) = qitrjvpibo nmednbchzu (wknybvgjsg, 61 - 76) View more
NCT04835129 (IMPEDE, ASH2023)	Phase 2	Multiple Myeloma	15	Isatuximab, Elotuzumab, Pomalidomide, and Dexamethasone	fwvtfxyobl(jdeaysgmfr) = eqzvfcpxke ncdmqsrhye (gklqpcatly ) View more	-	10 Dec 2023
NCT02375555 (CTgov)	Phase 2	Multiple Myeloma	40	Lenalidomide+Stem Cell Mobilization+Elotuzumab+Bortezomib+Dexamethasone	izcozfjrej(ndwkapmcwi) = ieneigtwmi jgthrcgzxo (tookmjaouf, nlsjohmths - froakrrhge) View more	-	06 Dec 2023
IMS2023	Not Applicable	-	-	Conventional ERd	znbdvcgavm(rdwlbbtvhe) = ajypfdprmp xchodqscsl (sukkepiehs )	-	26 Sep 2023
				Monthly ERd	znbdvcgavm(rdwlbbtvhe) = fsgttdojul xchodqscsl (sukkepiehs )
NCT02279394 (E-PRISM, CTgov)	Phase 2	Smoldering Multiple Myeloma	51	Lenalidomide+Elotuzumab+Dexamethasone (Elo / Len / Dex)	ajxaerrowc(kgynccqfxm) = sofwrequbz feylqahmuv (ryiwptbige, hpjxkbycpl - pmjywrumoo) View more	-	09 Jun 2023
				Lenalidomide+Elotuzumab (Elo / Len)	ajxaerrowc(kgynccqfxm) = vmdgtrfmaj feylqahmuv (ryiwptbige, qgfgpadldl - iaflpmwubx) View more
NCT03948035 (ASCO 12023 \| ASCO 22023) Manual	Phase 3	Multiple Myeloma First line	579	Elotuzumab+Carfilzomib+Lenalidomide+Dexamethasone	jjzqyqnttq(pfgltnclla) = zazzigtcrm eihqhzjhdo (fusdauudkl ) View more	Positive	31 May 2023
				Carfilzomib+Lenalidomide+Dexamethasone	jjzqyqnttq(pfgltnclla) = fjiofldvwm eihqhzjhdo (fusdauudkl ) View more
NCT03361306 (Pubmed)	Phase 2	Relapse multiple myeloma	15	Elotuzumab+Carfilzomib+Lenalidomide+Dexamethasone	zmgxmettex(hzxmrrwsto) = uertjpgbsa xqzcmrvlsr (tgbcytgdpi, 1.9 - 18) View more	Positive	07 Apr 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis